Planta Med 2010; 76(13): 1390-1404
DOI: 10.1055/s-0030-1250006
Reviews
© Georg Thieme Verlag KG Stuttgart · New York

Historic Perspectives on Annonaceous Acetogenins from the Chemical Bench to Preclinical Trials

Chih-Chuang Liaw1 , 2 , Tung-Ying Wu3 , Fang-Rong Chang3 , Yang-Chang Wu3 , 4
  • 1Graduate Institute of Pharmaceutical Chemistry, College of Pharmacy, China Medical University, Taichung, Taiwan
  • 2Department of Life Sciences, National Chung-Hsing University, Taichung, Taiwan
  • 3Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung, Taiwan
  • 4Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Further Information

Publication History

received Nov. 30, 2009 revised April 26, 2010

accepted April 28, 2010

Publication Date:
24 June 2010 (online)

Preview

Abstract

Studies on the Annonaceous acetogenins began after the first cytotoxic acetogenin, uvaricin, was isolated in 1982. This attractive finding made many medicinal and natural product chemists direct their efforts on the isolation and identification of these classes of compounds. As more Annonaceous acetogenins were isolated, more information about them was uncovered. From their structural identification to the total synthesis of natural product analogues and from cell-based screening and molecular-based targeting to animal testing, the mechanisms of action of the Annonaceous acetogenins became clearer. The purpose of this review is to give an account of recent studies on this class of compounds and their analogues, which will aid us not only in clarifying how the Annonaceous acetogenins act but also in establishing principles for the further development of this class of compounds.

References

Dr. Yang-Chang Wu

Graduate Institute of Natural Products
Kaohsiung Medical University

100 Shih-Chuan 1st Road

703 Kaohsiung

Taiwan

Republic of China

Phone: + 88 6 73 12 11 01ext. 21 97

Fax: + 88 6 73 11 47 73

Email: yachwu@kmu.edu.tw